Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 26, 2007

Goodwin Biotechnology to Produce Neogenix’ mAb for Pancreatic Cancer

  • Neogenix Oncology and Goodwin Biotechnology entered into an agreement for process development and manufacturing of Neogenix’ first therapeutic product. NPC-1C is a mAb intended for the treatment of advanced pancreatic cancer.

    Neogenix expects to begin Phase I and Phase II trials of the product during the first half of 2008.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »